Holen Sie sich die Stockscreener-App
11.68
2.01%
-0.24
Handel nachbörslich:
11.64
-0.04
-0.34%
Clearpoint Neuro Inc Aktie (CLPT) Neueste Nachrichten
retail investors who own 49% along with institutions invested in ClearPoint Neuro, Inc. (NASDAQ:CLPT) saw increase in their holdings value last week - simplywall.st
ClearPoint Neuro, Inc. (NASDAQ:CLPT) Q2 2025 Earnings Call Transcript - Insider Monkey
ClearPoint Neuro outlines global expansion plans and anticipates regulatory milestones while advancing cell and gene therapy initiatives - MSN
Retail investors account for 49% of ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) ownership, while institutions account for 42% - Yahoo Finance
ClearPoint Neuro, Inc. (CLPT) Reports Q2 Loss, Misses Revenue Estimates - MSN
ClearPoint Neuro (CLPT): Navigating Growth Amid Margin Pressures—Is Now the Time to Enter? - AInvest
ClearPoint Neuro Inc (CLPT) Q2 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... - Yahoo Finance
ClearPoint Neuro Inc (CLPT) Q2 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... By GuruFocus - Investing.com Canada
ClearPoint Neuro Achieves Record Revenue in Q2 2025 - TipRanks
ClearPoint Neuro 2025 Q2 Earnings Wider Losses Amid Revenue Growth - AInvest
ClearPoint Neuro's Q2 2025: Key Contradictions in MRI Utilization, GLP Compliance, and Revenue Growth - AInvest
ClearPoint Neuro Outlines Global Expansion Plans and Advances Cell and Gene Therapy Initiatives - AInvest
Earnings call transcript: Clearpoint Neuro’s Q2 2025 earnings miss forecasts By Investing.com - Investing.com Nigeria
Earnings call transcript: Clearpoint Neuro’s Q2 2025 earnings miss forecasts - Investing.com
ClearPoint Neuro, Inc. SEC 10-Q Report - TradingView
Clearpoint Neuro earnings missed, revenue fell short of estimates By Investing.com - Investing.com Canada
ClearPoint Neuro Q2 Loss Widens, Revenue Rises - MarketScreener
ClearPoint Neuro: Balancing Near-Term Earnings Pressure with Long-Term R&D-Driven Growth - AInvest
ClearPoint Neuro Reports Q2 2025 Record Revenue of $9.2mln, 17% YoY Increase - AInvest
ClearPoint Neuro Reports Second Quarter 2025 Results - ACCESS Newswire
How moving averages guide ClearPoint Neuro Inc. tradingPrice Spike Prediction for Active Traders - Newser
Is ClearPoint Neuro Inc. stock reversal real or fakeFree Day Trading Signals With High Precision - Newser
Will ClearPoint Neuro Inc. stock go up soonFree Entry Plan for Oversold Reversal Stocks - Newser
Why ClearPoint Neuro Inc. stock attracts strong analyst attentionQuick Profit Setup with Signal Forecast - Newser
Detecting support and resistance levels for ClearPoint Neuro Inc.Trade Safety Matrix for Conservative Traders - Newser
Is ClearPoint Neuro Inc. stock entering bullish territoryFree Community Entry Consensus Trade Ideas - Newser
How high can ClearPoint Neuro Inc. stock price go in 2025Free Reversal Alert Based on RSI Indicator - Newser
Chart based analysis of ClearPoint Neuro Inc. trendsFree Risk Controlled Short Term Trade Plans - Newser
Live market analysis of ClearPoint Neuro Inc.Smart Trend Analysis With Buy Point Cues - Newser
Is it too late to sell ClearPoint Neuro Inc.Support and Resistance Zone Summary Chart - Newser
Leading vs lagging indicators on ClearPoint Neuro Inc. performancePredictable Income Summary for Long-Term Trades - Newser
Is ClearPoint Neuro Inc. meeting your algorithmic filter criteriaTechnical Setup Guide for Daily Watchlist - Newser
ClearPoint Neuro (CLPT) to Release Earnings on Tuesday - Defense World
ClearPoint Neuro CLPT 2025Q2 Earnings Preview Upside Potential on Innovative Product Launch - AInvest
How ClearPoint Neuro Inc. stock performs during market volatilitySector-Wise Stock Strength Trend Analysis - Newser
Clearpoint Neuro Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
Lake Street Maintains ClearPoint Neuro(CLPT.US) With Buy Rating, Maintains Target Price $30 - 富途牛牛
Analyzing net buyer seller activity in ClearPoint Neuro Inc.Daily Market Momentum Summary and Strategy - Newser
ClearPoint Neuro Announces Progression of Key Partner Milestones throughout the Global Biologics and Drug Delivery Portfolio - ACCESS Newswire
Breakthrough: US Hospitals Complete First-Ever Commercial Gene Therapy Brain Treatments for Rare Disease - Stock Titan
How does ClearPoint Neuro Inc. generate profit in a changing economyHigh-profit capital plays - Jammu Links News
What catalysts could drive ClearPoint Neuro Inc. stock higher in 2025Achieve unparalleled market performance - Jammu Links News
What are analysts’ price targets for ClearPoint Neuro Inc. in the next 12 monthsFree Trend-Following Techniques - Jammu Links News
What are the technical indicators suggesting about ClearPoint Neuro Inc.Accelerated earnings growth - Jammu Links News
Should I hold or sell ClearPoint Neuro Inc. stock in 2025Invest confidently with professional market insights - Jammu Links News
Is ClearPoint Neuro Inc. stock overvalued or undervaluedExplosive wealth accumulation - Jammu Links News
How many analysts rate ClearPoint Neuro Inc. as a “Buy”Exceptional stock performance - Jammu Links News
How strong is ClearPoint Neuro Inc. company’s balance sheetBuild wealth faster with consistent growth stocks - Jammu Links News
ClearPoint Neuro Inc. Tests 50 Day MA After Sharp DeclineGrowth Based Stock Signal Screener Updated - beatles.ru
Is ClearPoint Neuro Inc. a good long term investmentFree Trend-Following Techniques - Jammu Links News
When is ClearPoint Neuro Inc. stock expected to show significant growthInvest smarter with daily market updates - Jammu Links News
What analysts say about ClearPoint Neuro Inc. stockAchieve breakthrough investment performance - Jammu Links News
Is ClearPoint Neuro Inc. a growth stock or a value stockUnlock powerful portfolio optimization tools - Jammu Links News
What drives ClearPoint Neuro Inc. stock priceAchieve superior returns with professional insights - Jammu Links News
What are ClearPoint Neuro Inc. company’s key revenue driversBuild wealth with steady, reliable stocks - jammulinksnews.com
How does ClearPoint Neuro Inc. compare to its industry peersInvest confidently with real-time data - jammulinksnews.com
2.30%
0.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):